東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

The diabetogenic effects of atypical...

University of Toronto (Canada).

Linked to FindBook

Google Book

Amazon

博客來

The diabetogenic effects of atypical antipsychotic medication: An animal model.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	The diabetogenic effects of atypical antipsychotic medication: An animal model./
Author:	Chintoh, Araba Fritsewa.
Description:	149 p.
Notes:	Source: Dissertation Abstracts International, Volume: 69-12, Section: B, page: 7310.
Contained By:	Dissertation Abstracts International69-12B.
Subject:	Biology, Neuroscience. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=NR44790
ISBN:	9780494447901

The diabetogenic effects of atypical antipsychotic medication: An animal model.
Chintoh, Araba Fritsewa.

The diabetogenic effects of atypical antipsychotic medication: An animal model. - 149 p.

Source: Dissertation Abstracts International, Volume: 69-12, Section: B, page: 7310.

Thesis (Ph.D.)--University of Toronto (Canada), 2008.

In the schizophrenia population, the increased prevalence of atypical antipsychotic use has been paralleled by an increase in reported incidence of obesity, type 2 diabetes, diabetic ketoacidosis and other metabolic abnormalities. These side effects contribute additional health risks to a population that is already burdened by issues of increased morbidity and mortality. We have developed an animal model to evaluate a number of variables relating to antipsychotic treatment and disruptions in metabolism. Investigating measures of insulin sensitivity, and secretion we assessed the chronic versus acute effects of atypical antipsychotic treatment, the differential effect of various antipsychotics, and a neural component by which the atypical antipsychotics induce glucose dysregulation. Chronic administration of olanzapine resulted in a decrease in insulin sensitivity. This insulin resistance was also observed with acute administration of olanzapine. Clozapine and risperidone induced insulin resistance, while ziprasidone and haloperidol did not change insulin sensitivity. We report novel data that show olanzapine and clozapine can have an immediate and significant impact on pancreatic beta cell function. We also initiated experiments to help uncover the pathways mediating antipsychotic-induced glucose dysregulation. Our results show that ICV injections of olanzapine affect both insulin sensitivity and secretion. Our acute data challenge prior notions that weight gain is the primary side effect of treatment with atypical antipsychotic medication and that the host of metabolic problems observed are merely a result of this increased adiposity. We highlight the significant risk to homeostatic glucoregulatory mechanisms in the acute phase of treatment with atypicals reiterating the need for clinicians to monitor metabolic status from the earliest stages of pharmacotherapy.

ISBN: 9780494447901Subjects--Topical Terms:

1017680
Biology, Neuroscience.

The diabetogenic effects of atypical antipsychotic medication: An animal model.
LDR:02722nam 2200265 a 45 001 858270
005 20100712
008 100712s2008 ||||||||||||||||| ||eng d
020 $a 9780494447901
035 $a (UMI)AAINR44790
035 $a AAINR44790
040 $a UMI $c UMI
100 1 $a Chintoh, Araba Fritsewa. $3 1025316
245 1 4 $a The diabetogenic effects of atypical antipsychotic medication: An animal model.
300 $a 149 p.
500 $a Source: Dissertation Abstracts International, Volume: 69-12, Section: B, page: 7310.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2008.
520 $a In the schizophrenia population, the increased prevalence of atypical antipsychotic use has been paralleled by an increase in reported incidence of obesity, type 2 diabetes, diabetic ketoacidosis and other metabolic abnormalities. These side effects contribute additional health risks to a population that is already burdened by issues of increased morbidity and mortality. We have developed an animal model to evaluate a number of variables relating to antipsychotic treatment and disruptions in metabolism. Investigating measures of insulin sensitivity, and secretion we assessed the chronic versus acute effects of atypical antipsychotic treatment, the differential effect of various antipsychotics, and a neural component by which the atypical antipsychotics induce glucose dysregulation. Chronic administration of olanzapine resulted in a decrease in insulin sensitivity. This insulin resistance was also observed with acute administration of olanzapine. Clozapine and risperidone induced insulin resistance, while ziprasidone and haloperidol did not change insulin sensitivity. We report novel data that show olanzapine and clozapine can have an immediate and significant impact on pancreatic beta cell function. We also initiated experiments to help uncover the pathways mediating antipsychotic-induced glucose dysregulation. Our results show that ICV injections of olanzapine affect both insulin sensitivity and secretion. Our acute data challenge prior notions that weight gain is the primary side effect of treatment with atypical antipsychotic medication and that the host of metabolic problems observed are merely a result of this increased adiposity. We highlight the significant risk to homeostatic glucoregulatory mechanisms in the acute phase of treatment with atypicals reiterating the need for clinicians to monitor metabolic status from the earliest stages of pharmacotherapy.
590 $a School code: 0779.
650 4 $a Biology, Neuroscience. $3 1017680
650 4 $a Health Sciences, Mental Health. $3 1017693
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0317
690 $a 0347
690 $a 0419
710 2 $a University of Toronto (Canada). $3 1017674
773 0 $t Dissertation Abstracts International $g 69-12B.
790 $a 0779
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoeng/servlet/advanced?query=NR44790